ES2173678T3 - Vacunacion no invasiva a traves de la piel. - Google Patents

Vacunacion no invasiva a traves de la piel.

Info

Publication number
ES2173678T3
ES2173678T3 ES99101479T ES99101479T ES2173678T3 ES 2173678 T3 ES2173678 T3 ES 2173678T3 ES 99101479 T ES99101479 T ES 99101479T ES 99101479 T ES99101479 T ES 99101479T ES 2173678 T3 ES2173678 T3 ES 2173678T3
Authority
ES
Spain
Prior art keywords
substance
drop
average diameter
substances
times lower
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99101479T
Other languages
English (en)
Spanish (es)
Inventor
Amia Chopra
Gregor Cevc
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idea AG
Original Assignee
Idea AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idea AG filed Critical Idea AG
Application granted granted Critical
Publication of ES2173678T3 publication Critical patent/ES2173678T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
ES99101479T 1999-01-27 1999-01-27 Vacunacion no invasiva a traves de la piel. Expired - Lifetime ES2173678T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99101479A EP1031346B1 (en) 1999-01-27 1999-01-27 Noninvasive vaccination through the skin

Publications (1)

Publication Number Publication Date
ES2173678T3 true ES2173678T3 (es) 2002-10-16

Family

ID=8237425

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99101479T Expired - Lifetime ES2173678T3 (es) 1999-01-27 1999-01-27 Vacunacion no invasiva a traves de la piel.

Country Status (19)

Country Link
US (1) US7867480B1 (https=)
EP (2) EP1031346B1 (https=)
JP (1) JP2002535350A (https=)
KR (2) KR20010112252A (https=)
CN (1) CN1230151C (https=)
AR (1) AR037312A1 (https=)
AT (1) ATE216875T1 (https=)
AU (1) AU778972B2 (https=)
BR (1) BR0007749A (https=)
CA (1) CA2360692C (https=)
DE (1) DE69901377T2 (https=)
DK (1) DK1031346T3 (https=)
ES (1) ES2173678T3 (https=)
HK (1) HK1030363A1 (https=)
HU (1) HU225170B1 (https=)
MX (1) MXPA01007657A (https=)
PT (1) PT1031346E (https=)
SI (1) SI1031346T1 (https=)
WO (1) WO2000044349A1 (https=)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
AU4932199A (en) 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
PT1031346E (pt) 1999-01-27 2002-09-30 Idea Ag Vacinacao nao invasiva atraves da pele
SI1031347T1 (en) 1999-01-27 2002-10-31 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
WO2001001962A1 (en) 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
DK1372708T3 (da) 2001-02-13 2008-10-20 Us Gov Sec Army Vaccine til transkutan immunisering mod rejsediarre
FR2822049B1 (fr) 2001-03-13 2003-08-01 Dbv Medica 1 Patch destine notamment a depister l'etat de sensibilisation d'un sujet a un allergene, procede de fabrication et utilisation
US7635488B2 (en) 2001-03-13 2009-12-22 Dbv Technologies Patches and uses thereof
EP1371664B1 (en) 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Wti modified peptide
US20020193729A1 (en) 2001-04-20 2002-12-19 Cormier Michel J.N. Microprojection array immunization patch and method
JP5230891B2 (ja) * 2001-09-28 2013-07-10 株式会社癌免疫研究所 抗原特異的ｔ細胞の新規な誘導方法
US20050002951A1 (en) * 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
ATE449612T1 (de) * 2002-10-02 2009-12-15 Nordic Vaccine Technology As Zusammensetzung zur impfung
US20040105881A1 (en) 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
KR101039758B1 (ko) 2006-04-28 2011-06-09 젤티크 애스세틱스, 인코포레이티드. 피하 지질 과다 세포의 개선된 냉각을 위한 치료 장치와함께 사용하기 위한 동결 방지제
US8192474B2 (en) 2006-09-26 2012-06-05 Zeltiq Aesthetics, Inc. Tissue treatment methods
US20080077201A1 (en) 2006-09-26 2008-03-27 Juniper Medical, Inc. Cooling devices with flexible sensors
US9132031B2 (en) 2006-09-26 2015-09-15 Zeltiq Aesthetics, Inc. Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile
US20080287839A1 (en) 2007-05-18 2008-11-20 Juniper Medical, Inc. Method of enhanced removal of heat from subcutaneous lipid-rich cells and treatment apparatus having an actuator
US8523927B2 (en) 2007-07-13 2013-09-03 Zeltiq Aesthetics, Inc. System for treating lipid-rich regions
EP3488833B1 (en) 2007-08-21 2025-10-22 Zeltiq Aesthetics, Inc. Monitoring the cooling of subcutaneous lipid-rich cells, such as the cooling of adipose tissue
FR2924349B1 (fr) 2007-12-03 2010-01-01 Dbv Tech Methode de desensibilitation aux allergenes
FR2924350B1 (fr) 2007-12-03 2010-08-13 Dbv Tech Procede et compositions pour la vaccination par voie cutanee
US8603073B2 (en) 2008-12-17 2013-12-10 Zeltiq Aesthetics, Inc. Systems and methods with interrupt/resume capabilities for treating subcutaneous lipid-rich cells
JP5519000B2 (ja) 2009-04-30 2014-06-11 ゼルティック エステティックス インコーポレイテッド 脂肪が豊富な皮下細胞から熱を除去するためのデバイス、システム、及び方法
WO2011000889A1 (en) * 2009-06-30 2011-01-06 William Henry Topical vaccine formulations and methods of treating drug addiction using same
GB2486371A (en) 2009-08-21 2012-06-13 Targeted Delivery Technologies Ltd Vesicular formulations
CA2787374A1 (en) 2010-01-25 2011-07-28 Zeltiq Aesthetics, Inc. Home-use applicators for non-invasively removing heat from subcutaneous lipid-rich cells via phase change coolants, and associated devices, systems and methods
US8676338B2 (en) 2010-07-20 2014-03-18 Zeltiq Aesthetics, Inc. Combined modality treatment systems, methods and apparatus for body contouring applications
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
GB201212010D0 (en) * 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
US8652457B2 (en) 2012-07-13 2014-02-18 Wisconsin Alumni Research Foundation Interleukin-10 peptides and antibodies thereof for inhibiting adverse effects of protozoan infection
US9545523B2 (en) 2013-03-14 2017-01-17 Zeltiq Aesthetics, Inc. Multi-modality treatment systems, methods and apparatus for altering subcutaneous lipid-rich tissue
US9844460B2 (en) 2013-03-14 2017-12-19 Zeltiq Aesthetics, Inc. Treatment systems with fluid mixing systems and fluid-cooled applicators and methods of using the same
ES2542088B1 (es) * 2014-01-29 2016-05-05 Enoc Solutions, S.L. Composición de azufre liposomado
ES2974899T3 (es) 2014-01-31 2024-07-02 Zeltiq Aesthetics Inc Composiciones y sistemas de tratamiento para el enfriamiento mejorado de tejido rico en lípidos
US10675176B1 (en) 2014-03-19 2020-06-09 Zeltiq Aesthetics, Inc. Treatment systems, devices, and methods for cooling targeted tissue
USD777338S1 (en) 2014-03-20 2017-01-24 Zeltiq Aesthetics, Inc. Cryotherapy applicator for cooling tissue
US10952891B1 (en) 2014-05-13 2021-03-23 Zeltiq Aesthetics, Inc. Treatment systems with adjustable gap applicators and methods for cooling tissue
US9821028B2 (en) * 2014-07-11 2017-11-21 Wisconsin Alumni Research Foundation Methods of controlling parasitic worms in animals
US10935174B2 (en) 2014-08-19 2021-03-02 Zeltiq Aesthetics, Inc. Stress relief couplings for cryotherapy apparatuses
US10568759B2 (en) 2014-08-19 2020-02-25 Zeltiq Aesthetics, Inc. Treatment systems, small volume applicators, and methods for treating submental tissue
ES2895910T3 (es) 2015-06-30 2022-02-23 Sequessome Tech Holdings Limited Composiciones multifásicas
US11154418B2 (en) 2015-10-19 2021-10-26 Zeltiq Aesthetics, Inc. Vascular treatment systems, cooling devices, and methods for cooling vascular structures
AU2017206118B2 (en) 2016-01-07 2021-09-30 Zeltiq Aesthetics, Inc. Temperature-dependent adhesion between applicator and skin during cooling of tissue
US10765552B2 (en) 2016-02-18 2020-09-08 Zeltiq Aesthetics, Inc. Cooling cup applicators with contoured heads and liner assemblies
US10682297B2 (en) 2016-05-10 2020-06-16 Zeltiq Aesthetics, Inc. Liposomes, emulsions, and methods for cryotherapy
US10555831B2 (en) 2016-05-10 2020-02-11 Zeltiq Aesthetics, Inc. Hydrogel substances and methods of cryotherapy
US11382790B2 (en) 2016-05-10 2022-07-12 Zeltiq Aesthetics, Inc. Skin freezing systems for treating acne and skin conditions
KR102480965B1 (ko) 2016-09-13 2022-12-26 알레간 인코포레이티드 안정화된 비단백질 클로스트리듐 독소 조성물
US11076879B2 (en) 2017-04-26 2021-08-03 Zeltiq Aesthetics, Inc. Shallow surface cryotherapy applicators and related technology
ES2940650T3 (es) 2017-09-12 2023-05-10 Wisconsin Alumni Res Found Péptidos del receptor 2 de interleucina-10, anticuerpos, composiciones y métodos de uso de los mismos
CN112789013A (zh) 2018-07-31 2021-05-11 斯尔替克美学股份有限公司 改善肤质的方法、装置和系统
CN114075551B (zh) * 2021-06-11 2024-01-26 华中农业大学 沙林鼠种布鲁氏菌脂多糖的单克隆抗体及应用

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2160326B1 (https=) 1971-11-19 1975-02-07 Anvar
US4185100A (en) 1976-05-13 1980-01-22 Johnson & Johnson Topical anti-inflammatory drug therapy
US4095596A (en) 1976-11-26 1978-06-20 Smithkline Corporation Nasal inhaler
US4369182A (en) 1978-09-27 1983-01-18 A. Nattermann & Cie Gmbh Inflammation-preventing pharmaceutical composition of oral administration
JPS55153713A (en) 1979-05-02 1980-11-29 Kureha Chem Ind Co Ltd Pharmaceutical preparation of ribosome containing active substance
US4383993A (en) 1980-05-30 1983-05-17 University Of Kentucky Research Foundation Nasal dosage forms containing natural female sex hormones
IL64397A0 (en) 1981-01-07 1982-02-28 Weder Hans G Process for the preparation of liposomal medicaments
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
USRE33273E (en) 1982-08-18 1990-07-24 Georgia Tech Research Corporation Materials having improved nonfouling characteristics and method of making same
FR2542998B1 (fr) 1983-03-24 1986-01-31 Rhone Poulenc Sante Nouvelle forme transdermale du dinitrate d'isosorbide
GB8321913D0 (en) 1983-08-15 1983-09-14 Acacia Chem Ltd Spray method
EP0152379A3 (de) 1984-02-15 1986-10-29 Ciba-Geigy Ag Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen enthaltend unilamellare Liposomen
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US4897269A (en) 1984-09-24 1990-01-30 Mezei Associates Limited Administration of drugs with multiphase liposomal delivery system
US4921706A (en) 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
IL79114A (en) 1985-08-07 1990-09-17 Allergan Pharma Method and composition for making liposomes
JPS6295134A (ja) 1985-10-21 1987-05-01 Nippon Saafuakutanto Kogyo Kk リポソ−ムの製造法
IN166447B (https=) 1985-11-27 1990-05-12 Ethicon Inc
DE3542773A1 (de) 1985-12-04 1987-06-11 Roehm Pharma Gmbh Hautwirksame pharmaka mit liposomen als wirkstofftraeger
US5244678A (en) 1986-01-14 1993-09-14 Ire-Celltarg S.A. Pharmaceutical composition containing a local anesthetic and/or centrally acting analgesic encapsulated in liposomes
FR2597367B1 (fr) 1986-04-22 1988-07-15 Oreal Procede pour faciliter la formation de spherules lipidiques en dispersion dans une phase aqueuse et pour ameliorer leur stabilite et leur taux d'encapsulation, et dispersions correspondantes.
KR900007831B1 (ko) 1986-11-28 1990-10-20 더 리포조옴 캄파니, 인코포레이티드 인지질 조성물
US4938970A (en) 1987-02-06 1990-07-03 Hustead Robert E Painless electrolyte solutions
DK86988A (da) 1987-02-25 1988-08-26 Takeda Chemical Industries Ltd Liposompraeparat og anvendelse deraf
CA1323306C (en) 1987-03-05 1993-10-19 Mircea C. Popescu Pharmacological agent-lipid solution preparation
US5154930A (en) 1987-03-05 1992-10-13 The Liposome Company, Inc. Pharmacological agent-lipid solution preparation
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US4855090A (en) 1987-03-13 1989-08-08 Micro-Pak, Inc. Method of producing high aqueous volume multilamellar vesicles
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
US5238613A (en) 1987-05-20 1993-08-24 Anderson David M Microporous materials
IL86650A0 (en) 1987-06-30 1988-11-30 Biophor Corp Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane
US4983395A (en) 1987-11-12 1991-01-08 Theratech Inc. Device for administering an active agent to the skin or mucosa
US4849224A (en) 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
US4937078A (en) 1988-08-26 1990-06-26 Mezei Associates Limited Liposomal local anesthetic and analgesic products
US5043165A (en) 1988-12-14 1991-08-27 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs
US5049392A (en) 1989-01-18 1991-09-17 The Liposome Company, Inc. Osmotically dependent vesicles
US4944948A (en) 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
JPH0334920A (ja) 1989-04-21 1991-02-14 Otsuka Pharmaceut Co Ltd リポソームに結合及至組合わされた生物活性化合物及びそれを含有する医薬
KR920703114A (ko) * 1989-07-14 1992-12-17 원본미기재 접합체 백신을 위한 시토킨 및 호르몬 운반체
ATE104862T1 (de) 1989-08-03 1994-05-15 Hisamitsu Pharmaceutical Co Hautcremezubereitung zur aeusserlichen verwendung.
US5104661A (en) 1989-08-14 1992-04-14 Technology Unlimited, Inc. Reverse loading of liposomes
US5209720A (en) 1989-12-22 1993-05-11 Unger Evan C Methods for providing localized therapeutic heat to biological tissues and fluids using gas filled liposomes
WO1992003122A1 (de) 1990-08-24 1992-03-05 Gregor Cevc Präparat zur wirkstoffapplikation in kleinsttröpfchenform
US6165500A (en) 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
JPH06505701A (ja) * 1990-09-10 1994-06-30 スクール・オブ・フアーマシー・ユニバーシテイ・オブ・ロンドン リポソーム
US5202125A (en) 1990-12-10 1993-04-13 Theratech, Inc. Method and systems for administering nitroglycerin transdermally at enhanced transdermal fluxes
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
JP2922017B2 (ja) 1991-03-25 1999-07-19 第一製薬株式会社 経口用脂質膜構造体
US5498420A (en) 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
HU223343B1 (hu) 1991-05-20 2004-06-28 Novartis Ag. Allil-amin-származékot tartalmazó gyógyászati készítmények és eljárás azok előállítására
US5498418A (en) 1991-06-10 1996-03-12 Schwarz Pharma Ag Nitroglycerine plaster and process for its production
IT1250691B (it) 1991-07-22 1995-04-21 Giancarlo Santus Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac.
GB9116610D0 (en) 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
EG20380A (en) 1991-10-16 1999-02-28 Richardson Vicks Inc Enhanced skin penetration system for improved topical delivery of drugs
EP0608320B1 (en) 1991-10-16 1998-01-28 Richardson-Vicks, Inc. Enhanced skin penetration system for improved topical delivery of drugs
US5985860A (en) 1992-06-03 1999-11-16 Toppo; Frank System for transdermal delivery of pain relieving substances
AU4673993A (en) 1992-07-28 1994-02-14 Procter & Gamble Company, The Pharmaceutical composition for topical use containing a crosslinked cationic polymer and an alkoxylated ether
ES2136105T3 (es) 1992-08-04 1999-11-16 Rhone Poulenc Rorer Gmbh Preparacion farmaceutica y/o cosmetica.
EP0616799B1 (en) 1993-03-24 2000-05-03 COLLABORATIVE LABORATORIES Inc. Cosmetic delivery system for salicylic acid and process for preparation of same
DE4336557C2 (de) 1993-05-06 1997-07-17 Lohmann Therapie Syst Lts Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
US5460820B1 (en) 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
FR2714601B1 (fr) 1993-12-30 1996-02-09 Oreal Composition dépigmentante pour le traitement simultané des couches superficielles et profondes, son utilisation.
US5716526A (en) 1994-01-14 1998-02-10 The Liposome Company, Inc. Method of separating materials from liposomes or lipid complexes
US5536263A (en) 1994-03-30 1996-07-16 Lectec Corporation Non-occulusive adhesive patch for applying medication to the skin
US5540934A (en) 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
ATE223202T1 (de) 1994-09-30 2002-09-15 Mika Pharma Ges Fuer Die Entwi Pharmazeutische zusammensetzung
IT1270678B (it) 1994-10-20 1997-05-07 Bayer Ag Liposomi al chetoprofen
DE4447287C1 (de) 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
US20020048596A1 (en) 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
US5763422A (en) 1995-01-27 1998-06-09 Board Of Regents, The University Of Texas System Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
IT1275955B1 (it) 1995-03-22 1997-10-24 Dompe Spa Formulazioni farmaceutiche in forma di gel tissotropico
US5654337A (en) 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
DE19512181C2 (de) 1995-03-31 2003-11-06 Hexal Pharma Gmbh Transdermales System mit Ramipril und/oder Trandolapril als ACE-Hemmer
DE19518221A1 (de) 1995-05-10 1996-11-14 Schering Ag Verwendung nichtsteroidaler Entzündungshemmer zur Verbesserung der physiologischen Verträglichkeit partikulärer pharmazeutischer Zubereitungen
US5653987A (en) 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
ZA967182B (en) 1995-08-24 1998-05-25 Magainin Pharma Asthma associated factors as targets for treating atopic allergies including asthma and related disorders.
US6214386B1 (en) 1995-11-22 2001-04-10 Recordati, S.A. Prompt-release oral pharmaceutical compositions for extemporaneous suspensions
US5783208A (en) 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
US5837289A (en) 1996-07-23 1998-11-17 Grasela; John C. Transdermal delivery of medications using a combination of penetration enhancers
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US5891472A (en) 1996-11-19 1999-04-06 Meri Charmyne Russell Treatment of equine laminitis
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
AU750702B2 (en) * 1997-05-01 2002-07-25 Chiron Corporation Use of virus-like particles as adjuvants
WO1998051281A1 (en) 1997-05-14 1998-11-19 Senju Pharmaceutical Co., Ltd. Aqueous suspension preparations with excellent redispersibility
WO1998058670A1 (en) * 1997-06-24 1998-12-30 Chiron Corporation Methods of immunizing adults using anti-meningococcal vaccine compositions
US6083996A (en) 1997-11-05 2000-07-04 Nexmed Holdings, Inc. Topical compositions for NSAI drug delivery
IT1298214B1 (it) 1998-01-28 1999-12-20 Dompe Spa Sali dell'acido (r) 2-(3-benzoilfenil) propionico e loro composizioni farmaceutiche.
US6193996B1 (en) 1998-04-02 2001-02-27 3M Innovative Properties Company Device for the transdermal delivery of diclofenac
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6726925B1 (en) 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
US6200598B1 (en) 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
SE9802864D0 (sv) 1998-08-27 1998-08-27 Pharmacia & Upjohn Ab Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
WO2000013684A2 (en) 1998-09-03 2000-03-16 Loma Linda University Medical Center Pharmaceutical composition and method for treatment of inflammation
MXPA00006196A (es) 1998-10-23 2003-07-21 Idea Ag Metodo para desarrollar, evaluar y utilizar asociaciones de macromoleculas y agregados complejos para obtener mejores tasas de asociacion/desasociacion controlable y carga efectiva.
DE69825495T2 (de) 1998-12-23 2005-07-28 Idea Ag Verbesserte formulierung zur topischen, nichtinvasiven anwendung in vivo
SI1031347T1 (en) 1999-01-27 2002-10-31 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
PT1031346E (pt) 1999-01-27 2002-09-30 Idea Ag Vacinacao nao invasiva atraves da pele
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6362227B1 (en) 1999-03-02 2002-03-26 Sepracor, Inc. Methods for the treatment of tinnitus and other disorders using R(−)ketoptofen
US7063859B1 (en) 1999-04-28 2006-06-20 Noven Pharmaceuticals, Inc. Barrier film lined backing layer composition and method for topical administration of active agents
AU766506B2 (en) 1999-06-18 2003-10-16 Powerlung Inc Pulmonary exercise device
WO2001001962A1 (en) 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
US6276598B1 (en) 1999-07-13 2001-08-21 Asm Assembly Automation Ltd. Method and apparatus for ball placement
JP2001036949A (ja) 1999-07-19 2001-02-09 Hitachi Ltd 無線通信方法および無線通信システム
US6685928B2 (en) 1999-12-07 2004-02-03 Rutgers, The State University Of New Jersey Therapeutic compositions and methods
US6248353B1 (en) 1999-12-10 2001-06-19 Dade Behring Inc. Reconstitution of purified membrane proteins into preformed liposomes
US6562370B2 (en) 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers
US6582724B2 (en) 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
US6645520B2 (en) 1999-12-16 2003-11-11 Dermatrends, Inc. Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers
US6673363B2 (en) 1999-12-16 2004-01-06 Dermatrends, Inc. Transdermal and topical administration of local anesthetic agents using basic enhancers
US6586000B2 (en) 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
EP1116485A3 (de) 2000-01-10 2002-01-16 Gerhard Dr. Gergely Instant-Granulat und Verfahren zu seiner Herstellung
US20020119188A1 (en) 2000-02-08 2002-08-29 Susan Niemiec Method of manufacturing liposomes
JP4763957B2 (ja) 2000-05-10 2011-08-31 オバン・エナジー・リミテッド メディアミリング
JP2004504357A (ja) 2000-07-26 2004-02-12 アルコン，インコーポレイテッド ポリマー性懸濁化剤を含有しない薬学的懸濁組成物
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US6868686B2 (en) 2002-04-04 2005-03-22 Matsushita Electric Industrial Co., Ltd. Refrigeration cycle apparatus
CN1703199B (zh) 2002-10-11 2010-04-28 伊迪亚股份公司 具有增强的可变形性、包含至少三种两亲性物质的聚集物,其用于改善通过半透屏障的转运以及非侵入性药物在体内、具体是通过皮肤的应用
US20040105881A1 (en) 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
US7387788B1 (en) 2003-10-10 2008-06-17 Antares Pharma Ipl Ag Pharmaceutical compositions of nicotine and methods of use thereof
WO2005063213A1 (en) 2003-12-19 2005-07-14 Biodelivery Sciences International, Inc. Rigid liposomal cochleate and methods of use and manufacture
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
CA2584475A1 (en) 2004-11-12 2006-05-18 Idea Ag Extended surface aggregates in the treatment of skin conditions

Also Published As

Publication number Publication date
ATE216875T1 (de) 2002-05-15
DE69901377T2 (de) 2003-01-02
AU2798800A (en) 2000-08-18
DK1031346T3 (da) 2002-08-12
BR0007749A (pt) 2001-11-13
WO2000044349A1 (en) 2000-08-03
PT1031346E (pt) 2002-09-30
EP1146858A1 (en) 2001-10-24
US7867480B1 (en) 2011-01-11
CN1230151C (zh) 2005-12-07
EP1031346B1 (en) 2002-05-02
AR037312A1 (es) 2004-11-03
CA2360692A1 (en) 2000-08-03
CN1342066A (zh) 2002-03-27
SI1031346T1 (en) 2002-08-31
MXPA01007657A (es) 2003-06-24
CA2360692C (en) 2011-01-04
KR20010112252A (ko) 2001-12-20
DE69901377D1 (de) 2002-06-06
HU225170B1 (en) 2006-07-28
HK1030363A1 (en) 2003-05-06
KR20070094662A (ko) 2007-09-20
JP2002535350A (ja) 2002-10-22
HUP0200315A2 (en) 2002-05-29
EP1031346A1 (en) 2000-08-30
AU778972B2 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
ES2173678T3 (es) Vacunacion no invasiva a traves de la piel.
AR052211A1 (es) Uso de vehiculos altamente adaptables para transporte transnasal y la preparacion de vacunas
BR9810614A (pt) Composições de vacinas de óleo-em-água
BRPI0411828A (pt) composições de limpeza à base de fluido lipofìlico capazes de liberar aromas
WO2005097834A3 (en) Liquid dispersion polymer compositions, their preparation and their use
HRPK20050421B3 (en) Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
Das et al. Natural permeation enhancer for transdermal drug delivery system and permeation evaluation: A review
AR062655A1 (es) Formulaciones de emulsiones de pickering
CO6180479A2 (es) Formulacion para tecnica de aniquilacion de machos (mat) para rociar con liberacion controlada y metodo de control de insectos
UY23276A1 (es) Procedimiento para preparar microcapsulas diseñadas para una liberación sostenida
BR0208647A (pt) Artigos de limpeza para múltiplas finalidades
US8574205B2 (en) Device for the cutaneous application of substances
NO20043001D0 (no) Farmasoytisk formulering omfattende cyklosporin og anvendelse derav
DE602005009915D1 (de) Zweiphasige Zusammensetzung enthaltend ein Natriumsalz eines Esters des Dimethiconcopolyols mit Sulfobernsteinsäure, und ihre Verwendung in der Kosmetik
ES1245127U (es) Textil repelente para juguetes
JP2005517715A (ja) バイティングミッジのにおいの追跡能力を抑制するための方法及び組成物
Cernikova et al. Investigation of permeation of acyclovir through skin using alaptide
Mathis et al. A revision of the shore-fly genus Hydrochasma Hendel (Diptera, Ephydridae)
US12220497B2 (en) Materials and methods for decontaminating animal integument
FR2890558B1 (fr) Microcapsules a coeur aqueux et leur utilisation en cosmetique
Klingner Fundamentals of percutaneous chemical absorption and decontamination
Burnett et al. Phytophotodermatitis mimicking jellyfish envenomation
Lotan Leveraging nematocysts toward human care
WO2000038778A1 (en) A method and article for debridement and detoxification of wounds
Brooks et al. Surfactant Effects on Skin Absorption of Model Organic Chemicals: Implications for Dermal Risk Assessment Studies

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1031346

Country of ref document: ES